A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin

Epilepsy Research

Volumn 35, Issue 3, 1999, Pages 253-255

  Rettie, Allan E ^a   Haining, Robert L ^a   Bajpai, Manoj ^a   Levy, René H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; Phenytoin; Warfarin

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; GENE PRODUCT; MUTANT PROTEIN; PHENYTOIN; RECOMBINANT PROTEIN; WARFARIN;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TOXICITY; ENZYME KINETICS; GENE MUTATION; GENETICS; HOMOZYGOSITY; INSECT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTICOAGULANTS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; INSECTS; KINETICS; PHENOTYPE; PHENYTOIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 0033065223     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(99)00017-0     Document Type: Article

References (7)

1. Bajpai M., Roskos L.K., Shen D.D., Levy R.H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 24:1996;1401-1403.
2. Bochner F., Hooper W.D., Eadie M.J., Tyrer J.H. Decreased capacity to metabolize diphenylhydantoin in a patient with hypersensitivity to warfarin. Aust. New Zealand J. Med. 5:1975;462-466.
3. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate selectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333:1996;447-458.
4. Meisheri Y.V. Simultaneous phenytoin and warfarin toxicity on chronic concomitant therapy. J. Assoc. Physicians India. 44:1996;661-662.
5. Miners J.O., Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in drug metabolism. Br. J. Clin. Pharmacol. 45:1998;525-538.
6. Steward D.J., Haining R.L., Henne K.R., Davis G., Rushmore T.H., Trager W.F., Rettie A.E. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7:1997;361-367.
7. Sullivan Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., Goldstein J.A. The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349.